Summary
Synopsis: Dextranomer1 is a hydrophilic dextran polymer advocated as a ‘cleansing agent’ for various types of exudating wounds or ulcers, including stasis (venous) ulcers and decubitus ulcers. It appears to exert its effect by a capillary action which absorbs wound exudate, as well as wound debris and micro-organisms, into the dextranomer beads or into the spaces between the beads, thus removing such products from the wound surface. Dextranomer is an aid to wound or ulcer management, and does not directly affect tissue repair in such ulcers, but as with other ‘cleansing’ agents or techniques, removal of debris (and possibly micro-organisms) from the wound could be expected to promote natural healing. Reports of its effectiveness in open studies, often in patients with seemingly resistant lesions, have been encouraging. Similarly, in comparative trials results have usually favoured dextranomer, but a clear indication of the relative efficacy and benefits as compared with other treatments used for exudating lesions has not yet emerged. Further well designed comparative studies are needed to provide such information.
General Properties: When applied to an exudating wound, dextranomer produces a ‘chromatographic like’ separation of constituents of the wound exudate and of other particles (e.g. bacteria, cellular debris) which may be found at the wound surface. Prostaglandins, hormones and other relatively small molecules freely enter the beads and are removed along with the beads at dressing changes. Larger particles such as micro-organisms and wound debris remain in the spaces between the beads and appear to be drawn by capillary flow toward the surface of the dextranomer layer, and thus away from the wound surface. It would seem that such a ‘cleansing’ effect is likely to generally promote healing, but the clinical significance of the removal from the wound surface of prostaglandins and other possible mediators of the inflammatory response, and of fibrinolytic substances, is unclear.
Therapeutic Trials: Dextranomer clearly aids in ‘cleansing’ exudate and wound debris from moist wound lesions. Indeed, its ability to remove accumulated exudate has resulted in some reports of transient initial apparent increases in wound size, due to removal of debris. Results reported in open studies with dextranomer, often in patients with chronic, seemingly nonresponsive ulcers or wounds, have seemed impressive, although such studies were often anecdotal in nature and must be interpreted with caution. Comparative studies in patients with decubitus or stasis ulcers or other wounds are made more difficult by the lack of an accepted standard treatment to use for comparison, and by the difficulty in objectively evaluating improvement in such lesions. Indeed, most of the ‘traditional’ treatments used have not been well studied. Nevertheless, well designed controlled studies are needed to clearly establish the efficacy of any agent used in wound treatment. A few controlled studies have been reported with dextranomer, and in those studies which made the best attempts to overcome design difficulties, dextranomer was usually more effective in many of the various evaluation parameters used (e.g. effect on pus and debris, pain, oedema, erythema, granulation, epithelialisation and in some studies wound healing) than treatment such as normal saline dressings, ‘conservative’ debridement with repeated gauze dressing changes, collagenase ointment or povidone iodine. However, a more clear picture of dextranomer’s relative efficacy as compared with these and other treatments used for exudating wounds or ulcers, such as Unna’s boot treatment, benzoyl peroxide, pressure bandaging with adequate exercising, etc., must await further well designed comparative studies.
Adverse Effects: Dextranomer is well tolerated. With the exception of isolated reports of erythema or slightly blistered skin, or other isolated occurrences for which a causative association with dextranomer was not clearly established, the only adverse effect seems to be pain on removal of the saturated beads from some wounds. This would probably also occur with other treatments during cleansing and dressing changes.
Method of Use: Dextranomer is poured on to a wound, which has been previously cleaned with normal saline, to a thickness of a least 3mm. Alternatively, if the wound is shallow or in an awkward place, a paste of dextranomer and glycerol (4:1) may be prepared just prior to use and applied in the same thickness. The wound is then bandaged, but room for expansion of the beads as they absorb fluid must be allowed. The dextranomer should be replaced on an individualised schedule, depending on the extent of exudation. When it assumes a grey to yellow colour it is saturated and no longer exerting a capillary effect. Normal saline solution should be used to remove the saturated gel and to wash the wound before adding fresh dextranomer. Most wounds require twice daily changes.
Similar content being viewed by others
References
Aberg, M.; Hedner, U.; Jacobsson, S. and Rothman, U.: Fibrionolytic activity in wound secretions. Scandinavian Journal of Plastic and Reconstructive Surgery 10: 103 (1976).
Arturson, G.; Hakelius, L.; Jacobsson, S. and Rothman, U.: A new topical agent (Debrisan) for the early treatment of the burned hand. Burns 4: 225 (1978).
Bewick, M. and Anderson, J.: A new method for treating infected wounds. Studies on the dextranomer (Debrisan): Case reports. Clinical Trials Journal 15: 120 (1978).
Botel, U.: Debrisorb® bei der Behandlung von Dekubital-Geschwuren. Eine empirische Studie. Fortschritte der Medizin 31: 1572 (1978).
Dagher, F.J.; Alongi, S.V. and Smith, A.: Bacterial studies of leg ulcers. Angiology 29: 641 (1978).
Editorial: Treating pressure sores. British Medical Journal 1: 1232 (1978).
Falk, J. and Tollerz, G.: Chronic tissue response to implantation of Debrisan®: An experimental study. Clinical Therapeutics 1: 185 (1977).
Floden, C.H. and Wikstrom, K.: Controlled clinical trial with dextranomer (Debrisan®) on venous leg ulcers. Current Therapeutic Research 24: 753 (1978).
Fraki, J.E.; Peltonen, L. and Hopsu-Havu, V.K.: Allergy to various components of topical preparations in stasis dermatitis and leg ulcer. Contact Dermatitis, in press (1979).
Frithz, A.: Behandling av decubitalsar med dextranpolymerparlor. Opuscula Medica 23: 167 (1978).
Ganrot, K.; Jacobsson, S. and Rothman, U.: A method for determining plasma proteins in inflammatory exudate absorbed by Sephadex. Scandinavian Journal of Plastic and Reconstructive Surgery 10: 73 (1976).
Groenewald, J.H.: The use of dextranomer (Debrisan) as a cleansing agent in the treatment of the post-phlebitic stasis ulcer. Unpublished study, on file Pharmacia (1979).
Hallbrook, T. and Lanner, E.: Serum zinc and healing of venous leg ulcers. Lancet 2: 780 (1972).
Hurme, H. and Linna, M.: Debrisan, a new treatment of postoperative infections in the anal and sacrococcygeal region. Unpublished report, Pharmacia (1978).
Jacobsson, S.; Jonsson, L.; Rank, F. and Rothman, U.: Studies on healing of Debrisan-treated wounds. Scandinavian Journal of Plastic and Reconstructive Surgery 10: 97 (1976).
Jacobsson, S.; Rothman, U.; Arturson, G.; Ganrot, K.; Haeger, K. and Juhlin, I.: A new principle for the cleansing of infected wounds. Scandinavian Journal of Plastic and Reconstructive Surgery 10: 65 (1976a).
Jonsson, G.: Testing of potential allergic contact sensitisation of Debrisan® in guinea pigs. Clinical Therapeutics 1: 260 (1978).
Kogler, H.: The management of post-surgical infected wounds: a one-year trial on lower-leg amputation stumps. The Management of Infected Wounds, Proceedings of a European Symposium held in The Hague, 9th September, p.47 (Excerpta Medica, 1978).
Krizek, T.J. and Robson, MC: Biology of Surgical Infection. Surgical Clinics of North America 55: 1261 (1975).
Lassus, A.; Karvonen, J. and Juvakoski, T.: Dextran polymer particles (Debrisan®) in the treatment of penile ulcers. Acta Dermatovener (Stockholm) 57: 361 (1977).
Lim, L.T.; Michuda, M. and Bergan, J.J.: The therapy of peripheral vascular ulcers — surgical management. Angiology 29: 654 (1978).
Lochbuhler, H.; Kaufmann, W. and Storz, W.L.: Ein neues Prinzip zur Behandlung infizierter Wunden. Therapiewoche 28: 2664 (1978).
Lookingbill, D.P.; Miller, S.H. and Knowles, R.C.: Bacteriology of chronic leg ulcers. Archives of Dermatology 114: 1765 (1978).
Lundberg, C. and Campbell, D.: Effect of Debrisan treatment on wound oedema in rats. Data on file, Pharmacia (1979).
McClement, E.J.W.; Shand, I.G. and Ramsay, B.: Pressure sores: A new method of treatment. British Journal of Clinical Practice 33: 21 (1979).
Molokhia, M.M. and Portnoy, B.: Serum zinc and healing of venous leg ulcers 1: 41 (1973).
Morrison, J.D.: Debrisan: An effective new wound cleanser. Scottish Medical Journal 23: 277 (1978).
Nakano, J.: General pharmacology of the prostaglandins; in Cuthbert (Ed) The Prostaglandins. Pharmacological and Therapeutic Advances, p.23 (William Heineman, London 1973).
Nierman, M.M.: Treatment of dermal and decubitus ulcers. Drugs 15: 226 (1978).
Olejniczak, S. and Zielinski, A.: Topical oxygen promotes healing of leg ulcers. Resident and Staff Physician 23: 165 (1977).
Paavolainen, P. and Sundell, B.: The effect of dextranomer (Debrisan®) on hand burns. A preliminary report on a new method in the treatment of hand burns. Annales Chirurgiae et Gynaecologiae 65: 313 (1976).
Pace, W.E.: Treatment of cutaneous ulcers with benzoyl peroxide. Canadian Medical Association Journal 115: 1101 (1976).
Pace, W.E.: Beads of a dextran polymer for the local treatment of cutaneous ulcers. Journal of Dermatologic Surgery and Oncology 4: 678 (1978).
Parish, L.C. and Collins, E.: Decubitus ulcers: a comparative study. Cutis 23: 106 (1979).
Phillips, A.; Davidson, M. and Greaves, M.W.: Venous leg ulceration: evaluation of zinc treatment, serum zinc and rate of healing. Clinical and Experimental Dermatology 2: 395 (1977).
Roenigk, H.: Dextranomer (Debrisan®) as a postoperative dermabrasion dressing. Presented at the 3rd International Symposium on Plastic and Reconstructive Surgery, New Oreleans, April 29–May 4 (1979).
Romasz, R.S.; Barnhart, B.S. and Schinagl, E.F.: Application of dextranomer beads (Debrisan®) in the treatment of exudating skin lesions: results of a cooperative study. Angiology 29: 675 (1978).
Salisbury, R.E.; Loveless, S.; Silverstein, P.A.; Wilmore, D.W.; Moylan, J.A., and Pruitt, B.A.: Postburn edema of the upper extremity: evaluation of present treatment. Journal of Trauma 13: 857 (1973).
Sawyer, P.N.; Dowbak, G.; Sophie, Z.; Feller, J. and Cohen, L.: A preliminary report of the efficacy of Debrisan® (dextranomer) in the debridement of cutaneous ulcers. Surgery, 85: 201 (1979).
Sawyer, P.N.; Sophie, Z.; Dowbak, G.; Cohen, L. and Feller, J.: New approaches in the therapy of the peripheral vascular ulcer. Angiology 29: 666 (1978).
Soul, J.: A trial of Debrisan in the cleansing of infected surgical wounds. British Journal of Clinical Practice 32: 172 (1978).
Wallgren, R.: The therapeutic effect of Debrisan®. A controlled clinical trial performed at the Aurora Hospital, Helsinki. On file, Pharmacia (1975).
Zelikovski, A.; Agranati, A.; Sternberg, A.; Hadad, M. and Urca, I.: Conservative treatment of stasis ulcers of the lower limb. Angiology 29: 832 (1978).
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: F. J. Dagher, Vascular and Transplantation Services, Department of Surgery, University of Maryland, Baltimore, Maryland, USA; C.-H. Floden, Department of Dermatology, Centralsjukhuset, Karlstad, Sweden; C.L. Fox, Jr., Department of Surgery, College of Physicians and Surgeons of Columbia University, New York, USA; A. Frithz, Department of Dermatology, Sodersjukhuset, Stockholm, Sweden; S. Jacobsson, Plastik-kirurgiska Kliniken, Allmanna sjukhuset, Malmo, Sweden; H.I. Lippmann, Vascular Clinic, Albert Einstein College of Medicine of Yeshiva University, New York, USA; D.P. Lookingbill, Division of Dermatology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania, USA; I.F.K. Muir, Woodend General Hospital, Aberdeen, Scotland; P. Paavolainen, Helsingen Yliopistollinen Keskussairaala, Helsinki, Finland; B.A. Pruitt, Jr., US Army Institute of Surgical Research, Brooke Army Medical Center, Fort Sam Houston, Texas, USA; P.N. Sawyer, Department of Surgery and Surgical Research, State University of New York, Downstate Medical Center, Brooklyn, New York, USA.
‘Debrisan’ (Pharmacia).
Rights and permissions
About this article
Cite this article
Heel, R.C., Morton, P., Brogden, R.N. et al. Dextranomer: A Review of its General Properties and Therapeutic Efficacy. Drugs 18, 89–102 (1979). https://doi.org/10.2165/00003495-197918020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197918020-00001